eriodictyol has been researched along with Cognitive Decline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, C; Yuan, M; Zhang, L | 1 |
| Gao, Y; He, P; Liu, X; Liu, Z; Xiao, C; Yan, S; Zhang, S; Zheng, J | 1 |
2 other study(ies) available for eriodictyol and Cognitive Decline
| Article | Year |
|---|---|
Eriodictyol produces antidepressant-like effects and ameliorates cognitive impairments induced by chronic stress.
Topics: Animals; Antidepressive Agents; Chronic Disease; Cognitive Dysfunction; Dose-Response Relationship, Drug; Flavanones; Lipopolysaccharides; Male; Rats; Rats, Sprague-Dawley; Stress, Psychological | 2020 |
Eriodictyol Attenuates LPS-Induced Neuroinflammation, Amyloidogenesis, and Cognitive Impairments via the Inhibition of NF-κB in Male C57BL/6J Mice and BV2 Microglial Cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Cognitive Dysfunction; Flavanones; Humans; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microglia; NF-kappa B | 2018 |